Suven Life Sciences secures patents

The company has been granted three patents for its neurodegenrative drug

id-100108240

The company has received patents from Eurasia, Japan and Mexico

Suven Life Sciences has announced the grant of three product patent. One each from Eurasia (020227), Japan (5540099) and Mexico (319429) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases. These Patents are valid through 2029.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson, and Schizophrenia.

With these new patents, Suven has a total of thirteen granted patents from Eurasia, twelve granted patents from Japan and seventeen product patents from Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," said Mr Venkat Jasti, CEO of Suven.

 

 

2 Comment Comment 1 - 2 of 2
comment

Gopalakrishna Ramaswamy 1 January 2015 at 04:34 PM

Congratulations to Suven Life Sciences team. All the best to take these molecules to globally.

Reply

comment

Gopalakrishna Ramaswamy 1 January 2015 at 04:15 PM

Congratulations to Suven Life Sciences team. All the best to take these molecules to global patients.

Reply

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X